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Background: Recent studies show that microRNA-145 (miR-145) might be an attractive tumor biomarker of
considerable prognostic value. To clarify the preliminary predictive value of miR-145 for prognosis in various
malignant neoplasms, we conducted a meta-analysis of 18 relevant studies.
Methods: Eligible studies were identified by searching the online databases PubMed, EMBASE, and Web of
Science up to March 2014. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and
disease progress were calculated to investigate the association with miR-145 expression.
Results: In total, 18 eligible studies were included in this meta-analysis. Our results showed that upregulated
miR-145 significantly predicted a favorable overall survival (OS) (HR = 0.47, 95% CI 0.31 to 0.72), but failed to show a
significant relation with disease prognosis. In stratified analyses, high miR-145 expression predicted favorable OS in
both Whites and Asians but the intensity of the association in Whites (HR = 0.67, 95% CI 0.47 to 0.95) was not as
strong as in Asians (HR = 0.35, 95% CI 0.19 to 0.64). High miR-145 expression also predicted better progression-free
survival (PFS) in Asians (HR = 0.43, 95% CI 0.21 to 0.89), but not in Whites. In addition, a significantly favorable OS
associated with upregulated miR-145 expression was observed in both squamous cell (SCC) (HR = 0.34, 95% CI 0.13
to 0.93) and glioblastoma (HR = 0.72, 95% CI 0.52 to 0.99).
Conclusions: Our findings indicate that high miR-145 expression is better at predicting patient survival rather than
disease progression for malignant tumors, especially for SCC and glioblastoma in Asians. Considering the insufficient
evidence, further investigations and more studies are needed.
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Emerging studies have demonstrated that deregulated
expression of microRNAs (miRNAs) correlates with can-
cer prognosis because of the distinct expression profiles of
these miRNAs in cancerous tissues compared with normal
tissues [1-3]. A large number of studies have put particular
emphasis on the upregulated expression of various miR-
NAs that are usually associated with poor prognosis in
malignant neoplasms, known as ‘hazardous miRNAs’ [1-5].
However, some recent studies have transferred attention to
the downregulated expression of several miRNAs that are* Correspondence: yj197912@163.com
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unless otherwise stated.associated with an unfavorable cancer prognosis [5-7],
which are categorized as ‘protective miRNAs’ and are
much less common than hazardous miRNAs. In these
reported protective miRNAs, miR-145 has been studied
relatively intensively and thoroughly for cancer prognosis.
The anti-tumor effects of miR-145 with various mech-
anisms have been demonstrated by abundant clinical
and basic studies [8-11]. In hepatocellular carcinoma
(HCC), miR-145 was found to target a number of genes
along the signaling pathway of insulin-like growth factor
(IGF), including IGF-1 receptor, insulin receptor substrate-1
(IRS-1), and IRS-2, all of which are directly downregulated
by miR-145 [8]. Law et al. also confirmed that miR-145
modulates the IGF signaling pathway by reducing its down-
stream mediator, the active β-catenin [9]. In addition, p53d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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after which miR-145 can silence c-Myc, demonstrating
the role of miR-145 in p53-mediated c-Myc repression
[10]. In head and neck squamous cell carcinoma (SCC),
miR-145 also can target the SOX9/ADAM17 axis to in-
hibit tumor-initiating cells and IL-6-mediated paracrine
effects [11] (Figure 1).
As a tumor suppressor, miR-145 has been reported to
have downregulated expression in various cancer tissues,
although the targets of miR-145 have not been defini-
tively identified [8-11]. A number of studies have shown
significant associations between low miR-145 expression
and poor cancer prognosis, but other studies did not
find any significant association, and still others showed a
negative correlation [12,13] that might cast doubt on the
anti-oncogenic role of miR-145. However, in spite of
these contradictory results, miR-145 is still an attractive
tumor biomarker with considerable prognostic value, and
deserves to be further investigated. Therefore, we conduc-
ted a meta-analysis to clarify the preliminary predictive
value of miR-145 in tumor prognoses.
Methods
Search strategy, eligibility criteria, and data extraction
We performed this meta-analysis following the guide-
lines of the Meta-analysis of Observational Studies in
Epidemiology group (MOOSE) [14]. Because newly pub-
lished original works may get overlooked, we searched
PubMed, EMBASE, and Web of Science up to March
2014 to identify relevant studies. Several combinationsFigure 1 Reported mechanisms for the anti-tumor effect and expressof the following keywords were simultaneously applied:
‘cancer’, ‘carcinoma’, ‘neoplasm’, ‘tumour’, ‘tumor’, ‘micro-
RNA-145’, ‘microrna-145’, ‘miRNA-145’, ‘miR-145’, ‘sur-
vival’, ‘recurrence’, ‘relapse’, ‘metastasis’, and ‘prognosis’.
Studies were considered eligible for further evaluation
when they met the following criteria: studies that 1) fo-
cused on patients with any malignant neoplasmI and 2)
investigated the association between miR-145 expression
and prognosis outcomes. In addition, the bibliographies of
all eligible studies were reviewed for additional relevant
publications to supplement our literature search. When
studies deriving from the same series of study subjects
were reported in multiple publications, only the most
recent and the most complete studies were used for the
meta-analysis.
To fit the eligible criteria, selected studies had to be
published in English, had to focus on human malignant
tumors, and had to have performed stratified analyses
on patient prognoses using the dichotomous expression
levels of miR-145. Studies lacking the key data of hazard
ratios (HRs) or confidence intervals (CIs), without survival
curves, were not analyzed. A flow diagram of the study
selection process is presented in Figure 2.
Extracted data elements included the following: 1) first
author name and publication year; 2) characteristics of
the studied population, including patient nationality, eth-
nicity, disease, pathological type, and sample category; 3)
detection method and cut-off definition; 4) follow-up time;
and 5) HRs of elevated miR-145 expression for overall
survival (OS), recurrence-free survival (RFS), disease-ion regulation of microRNA-145 (miR-145).
Figure 2 Flow diagram of the study selection process.
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progression-free survival (PFS), along with their 95% CIs
and P values. If HRs and 95% CIs were not directly
reported in publications, the total numbers of cases and
deaths in each group were extracted to calculate HRs [15].
If only Kaplan-Meier curves were available, data were
extracted from graphical survival plots to extrapolate HRs
and 95% CIs, using previously described methods [16,17].
All the aforementioned data are comprehensively detailed
in Table 1 and Table 2.
Statistical analysis
The aggregation of HRs and 95% CIs were calculated
following Tierney method [17]. Forest plots were used to
estimate the effect of miR-145 expression on patient sur-
vival and disease progress. Heterogeneity test for pooled
HRs was verified by Cochran Q-test and Higgins I-squared
statistic (I2). Heterogeneity was considered statistically sig-
nificant at P < 0.1 or if the percentage of I2 was greater than
50%; if so, the random-effects model (DerSimonian and
Laird method) was applied, otherwise, the fixed-effects
model (Mantel-Haenszel test) was used [18]. In addition,
we also executed stratified analyses to minimize the influ-
ence of heterogeneity by classifying analyzed studies into
subgroups based on similar characteristics. Publication bias
was estimated by Egger linear regression test with a funnel
plot [19]. All P values were two-sided and a P < 0.05 was
considered statistically significant. All statistical analyseswere conducted with Stata® (v11; StataCorp LP, College
Station, TX, USA).
Results
Summary of analyzed studies
In total, 447 studies focusing on the relationship between
miR-145 and cancer were identified from an initial online
literature search, and 363 studies were excluded by man-
ual screening of titles and abstracts. The full text of the
remaining 84 studies was further evaluated, and finally, 18
studies [5-7,9,11-13,20-30] were considered eligible for
this meta-analysis (Table 1). The selection process and ex-
cluding reasons of candidate studies are shown in detail in
Figure 2.
Of the 18 included studies, 11 studies in our meta-
analysis were carried out with White subjects, and 7 with
Asian subjects. Quantitative reverse transcription PCR
(qRT-PCR) was used to measure miR-145 expression in
17 studies, while the remaining study used microarray.
The malignant neoplasms studied consisted of glioma,
non-small cell lung cancer (NSCLC), head and neck can-
cer (HNC), prostate cancer (PCa), osteosarcoma, HCC,
and colorectal, esophageal, cervical, breast, and ovarian
cancers. The pathological types comprised glioblastoma,
adenocarcinoma, small cell carcinoma, sarcoma, and squa-
mous cell carcinoma (SCC). Seven of the analyzed studies
reported the OS of patients, eight focused on PFS (includ-
ing RFS, DFS, and MFS), and three investigated both OS
Table 1 Main characteristics of studies included in the meta-analysis






















Lee, 2013 [5] USA White R Brain glioma Glioblastoma Tissue OS Reported 120
Saija, 2013 [6] Finland White R Brain glioma Glioblastoma Tissue OS SC 135
Campayo, 2013 [7] Spain White R NSCLC Adeno/SCC Tissue RFS SC 36
Yu, 2013 [11] China Asian R HNC SCC Tissue OS SC 60
Avgeris, 2013 [20] Greece White R Prostate cancer Adeno Tissue DFS Reported 72
Tang, 2013 [21] China Asian R Osteosarcoma Sarcoma Tissue OS/DFS Reported 152
Tanaka, 2013 [22] Japan Asian R Esophageal cancer SCC Serum PFSa SC 39
Speranza, 2012 [23] Italy White R Brain glioma Glioblastoma Tissue OS SC 18
Kang, 2012 [24] Korea Asian R Prostate cancer Adeno Tissue RFS Reported 55
Schee, 2012 [25] Norway White R CRC Adeno Tissue MFS SC 60
Law, 2012 [9] China Asian R HCC Adeno Tissue DFS SC 144
Ko, 2012 [12] Canada White R Esophageal cancer SCC Tissue DFS SC 32
Huang, 2012 [26] China Asian R Cervical cancer Small cell carcinoma Tissue OS SC 70
Marchini, 2011 [27] Italy White R EOC Adeno Tissue OS/PFS Reported 143
Radojicic, 2011 [28] Greece White R Breast cancer Adeno Tissue OS/DFS SC 120
Leite, 2011 [13] Brazil White R Prostate cancer Adeno Tissue RFS Reported 122
Hamano, 2011 [29] Japan Asian R Esophageal cancer SCC Tissue OS SC 97
Drebber, 2011 [30] Germany White R Rectal cancer Adeno Tissue OS SC 72
Adeno, adenocarcinoma; CRC, colorectal cancer; DFS, disease-free surviva; EOC, epithelial ovarian cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer;
HR, hazard ratio; MFS, metastasis-free survival; NSCLC, non-small cell lung cancer; OS, overall survival; P, prospective; PFS, progression-free survival; R, retrospective;
RCC, renal cell carcinoma; RFS, relapse-free survival; SC, survival curve; SCC, squamous cell carcinoma.
aPFS included any of the following: DFS, MFS or RFS.
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maximal follow-up time ranged from 18 to 152 months.
The main characteristics of analyzed studies are systematic-
ally listed in Table 1 and Table 2.
Overall survival associated with miR-145 expression
Ten articles analyzed OS, and seven of these showed
statistical significance (Table 2). Significant heterogeneity
between studies was observed (P < 0.001, I2 = 83.9%), thus
a random-effects model was applied to estimate a pooled
HR along with 95% CI. Our results showed that upre-
gulated miR-145 expression was a significant predictor of
favorable OS (pooled HR = 0.47, 95% CI 0.31 to 0.72)
(Table 3; Figure 3A).
Furthermore, we performed stratified analyses by clas-
sifying studies into subgroups of ethnicity and main
pathologic type (Table 3; Figure 3A; Figure 4A). First, six
studies in the White subgroup displayed a better OS
associated with elevated miR-145 expression (pooled
HR = 0.67, 95% CI 0.47 to 0.95) by a random-effects
model (P = 0.032, I2 = 59.1%). The other four studies
in Asians also showed that high miR-145 expression
was significantly associated with a favorable OS (pooled
HR = 0.35, 95% CI 0.19 to 0.64) using a random model(P = 0.025, I2 = 67.9%). Second, eight studies were divided
into three main pathologic subgroups of adenocarcinoma,
SCC, and glioblastoma. High miR-145 expression was
found to be significantly associated with favorable OS in
both SCC (pooled HR = 0.34, 95% CI 0.13 to 0.93) and
glioblastoma (pooled HR = 0.72, 95% CI 0.52 to 0.99). No
significant association was found for the adenocarcinoma
subgroup (pooled HR = 0.47, 95% CI 0.14 to 1.61).
Tumor progression associated with miR-145 expression
We analyzed tumor progression by combining disease
recurrence and metastasis. Eleven studies were included
in PFS analysis, and five showed statistical significance
(Table 2). A random-effects model was applied to calcu-
late the pooled HR along with 95% CI for the significant
heterogeneity (P < 0.001, I2 = 72.9%), but failed to show
any statistical significance (pooled HR = 0.87, 95% CI 0.51
to 1.47) (Table 3).
Stratified analyses displayed that high miR-145 expres-
sion was a significantly favorable prediction for tumor
progression in Asian subgroup of four studies (pooled
HR = 0.43, 95% CI 0.21 to 0.89) by a random-effects
model (P = 0.090, I2 = 53.8%), but failed to show a signifi-
cant association between miR-145 expression and tumor








Cases, n OS PFSa
High expression Low expression HR (95% CI) P HR (95% CI) P
Lee 2013 [5] qRT-PCR Mean NM NM 0.84 (0.74 to 0.97) (M)b 0.017 NM NM
Saija 2013 [6] Microarray Three-fold 215 53 0.67 (0.49 to 0.92) (U)b <0.01 NM NM
Campayo 2013 [7] qRT-PCR Mean 56 14 NM NM 0.30 (0.12 to 0.73) (M)b 0.015
Yu 2013 [11] qRT-PCR Two-fold 125 125 0.21 (0.14 to 0.31) (U)b <0.01 NM NM
Avgeris 2013 [20] qRT-PCR Mean 35 27 NM NM 0.79 (0.31 to 2.04) (M) 0.629
Tang 2013 [21] qRT-PCR Median 77 89 0.28 (0.11 to 0.91) (M) 0.010 0.24 (0.09 to 0.83) (M) 0.008
Tanaka 2013 [22] qRT-PCR Median 32 32 NM NM 0.89 (0.38 to 2.09) (U)b 0.809
Speranza 2012 [23] qRT-PCR Median 8 7 0.23 (0.06 to 0.83) (U)b 0.018 NM NM
Kang 2012 [24] qRT-PCR Median NM NM NM NM 0.68 (0.22 to 2.14) (U) 0.510
Schee 2012 [25] qRT-PCR Median 96 97 NM NM 1.41 (0.76 to 2.59) (U)b 0.290
Law 2012 [9] qRT-PCR 1.5-fold 15 32 NM NM 0.22 (0.09 to 0.57) (U)b <0.05
Ko 2012 [12] qRT-PCR Two-fold 13 12 NM NM 2.56 (1.06 to 6.18) (U)b 0.037
Huang 2012 [26] qRT-PCR Mean 22 22 0.47 (0.17 to 1.33) (M)b 0.072 NM NM
Marchini 2011 [27] qRT-PCR Median NM NM 0.14 (0.03 to 0.75) (M) 0.022 2.24 (0.47 to 10.59) (M) 0.309
Radojicic 2011 [28] qRT-PCR Mean 38 49 1.19 (0.58 to 2.45) (U)b 0.824 1.04 (0.52 to 2.09) (U)b 0.882
Leite 2011 [13] qRT-PCR Mean NM NM NM NM 3.35 (1.32 to 8.50) (M) 0.011
Hamano 2011 [29] qRT-PCR Median 49 49 0.58 (0.33 to 0.99) (U)b 0.023 NM NM
Drebber 2011 [30] qRT-PCR Median 35 15 0.38 (0.11 to 1.31) (U)b 0.244 NM NM
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; M, multivariate analysis; MFS, metastasis-free survival; NM, not mentioned; OS, overall survival;
PFS, progression-free survival; qRT-PCR, quantitative real-time PCR; RFS, relapse-free survival; U, univariate analysis.
aPFS included any of the following: DFS, MFS or RFS.
bHR and 95% CI calculated by survival curve.
Table 3 Patient survival or disease progression by total and stratified analyses
Subgroup OS PFSa
n HR (95% CI) P value n HR (95% CI) P value
Total 10 0.47 (0.31 to 0.72)b <0.001 11 0.87 (0.51 to 1.47)b 0.596
Subtotal by ethnicity
White 6 0.67 (0.47 to 0.95)b 0.026 7 1.27 (0.71 to 2.26)b 0.420
Asian 4 0.35 (0.19 to 0.64)b 0.001 4 0.43 (0.21 to 0.89)b 0.024
Subtotal by disease
Brain glioma 3 0.72 (0.52 to 0.99)b 0.045 – – –
Prostate cancer – – – 3 1.25 (0.45 to 3.48)b 0.671
Esophageal cancer – – – 2 1.50 (0.53 to 4.22)b 0.443
Subtotal by main pathology
Adeno 3 0.47 (0.14 to 1.61)b 0.228 7 1.01 (0.55 to 1.89)b 0.965
SCC 2 0.34 (0.13 to 0.93)b 0.035 2 1.50 (0.53 to 4.22)b 0.443
Glioblastoma 3 0.72 (0.52 to 0.99)b 0.045 – – –
OS, overall survival; PFS, progression-free survival including any of relapse-free survival (RFS), disease-free survival (DFS), and metastasis-free survival (MFS); N, number of
studies; HR, hazard ratio; CI, confidence interval; SqCa, squamous carcinoma; Adeno, adenocarcinoma.
aPFS included any of the following: DFS, MFS or RFS.
bThe HRs and 95% CIs of the analyzed studies were pooled by the random-effects model if the P value for heterogeneity was less than 0.10 or I2 was greater
than 50%.
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Figure 3 Forest plots of merged analyses for patient survival or disease progression associated with microRNA-145 (miR-145) expression,
and Begg funnel plots of publication bias test. (A) Forest plots for overall and ethnic subtotal analyses of overall survival. Squares and horizontal
lines correspond to study-specific hazard ratios (HRs) and 95% confidence intervals (CIs), respectively. The area of the squares correlates the weight,
and the diamonds represent summary HRs and 95% CIs. (B) Forest plots for overall and ethnic subtotal analyses of progression-free survival (PFS).
(C) Begg funnel plots of publication bias test for overall merged analysis of overall survival. Each point represents a separate study. (D) Begg funnel
plots of publication bias test for overall merged analysis of PFS.
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HR = 1.27, 95% CI 0.71 to 2.26) (Table 3; Figure 3B). In
addition, no significant relevance was observed in sub-
groups of PCa (pooled HR = 1.25, 95% CI 0.45 to 3.48),
adenocarcinoma (pooled HR = 1.01, 95% CI 0.55 to 1.89),
and squamous carcinoma (pooled HR = 1.50, 95% CI 0.53
to 4.22) (Table 3; Figure 4B; Figure 4C).Publication bias
Publication bias of total analyses for patient survival and
tumor progression was evaluated by funnel plots and
Egger tests. As expected, the funnel plots were symmet-
rical and the P values of the Egger test were 0.076 for OS
and 0.566 for PFS, suggesting the absence of significant
publication bias (Figure 3C, D).Discussion
Aberrant expression of miRNAs has been found in vari-
ous diseases including human carcinomas, and specific
miRNAs have been shown to play crucial roles in the
biological behaviors of initiation, progression, migration,
and invasion of tumors [31-35]. Compared with mRNAs
and proteins, miRNAs are more stable and not easily
degraded. They can be detected accurately by qRT-PCR
in both fresh and formalin-fixed tissues [36], and can
also be quantified in serum, urine, or saliva samples
[37]. Therefore, miRNAs are considered promising tumor
biomarkers for early diagnosis and accurate progno-
sis, as well as potential targets for clinical treatment
[1,3,22,36,38,39].
Recent researches have shown that downregulation of
miR-145 expression is significantly associated with poor
Figure 4 Forest plots of merged analyses for patient survival or disease progression associated with microRNA-145 (miR-145) expression
in different subgroups of pathologic types and malignant diseases. (A) Forest plots for the merged analyses of overall survival in different
pathological subgroups. Squares and horizontal lines correspond to study-specific hazard ratios (HRs) and 95% confidence intervals (CIs), respectively.
The area of the squares correlates the weight, and the diamonds represent summary HRs and 95% CIs. (B) Forest plots for the merged analyses of
progression-free survival (PFS) in different pathological type subgroups. (C) Forest plots for the merged analyses of PFS in different malignant
disease subgroups.
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[5-9,11,21,27,29]. Lee et al. reported that low miR-145
expression in glial tumors predicted poor prognosis, and
upregulated miR-145 significantly decreased the migration
and invasion of glioma cells by targeting connective tissue
growth factor [5]. Campayo et al. found that low miR-145
expression independently predicted a shorter time to
relapse in patients with NSCLC [7]. In addition, down-
regulated miR-145 expression was found in PCa tissue
compared with benign prostatic hyperplasia tissue, and
this was correlated with higher Gleason score, advanced
clinical stage, larger tumor diameter, and higher levels of
prostate-specific antigen. The loss of the anti-oncogenic
miR-145 may result in higher risk of biochemical recur-
rence, shorter DFS, and worse OS in patients with PCa
[20]. In the present meta-analysis, we gathered the avail-
able evidence from all relevant studies to evaluate the
prognostic values of miR-145 for malignant neoplasms.
Our results demonstrated that high miR-145 expression
was significantly correlated with favorable OS in overall
analyses (P < 0.001), but did not exhibit an obvious
association with tumor progression (P = 0.596) (Table 3).
These inconsistent outcomes might hint at dissimilar
potential mechanisms that affect patient survival or tumor
progression.
Studies on miRNA expression profiles have indicated
that downregulation of miR-145 is a common event in
malignant disease [5,21,26]. However, little is known
about why miR-145 is often downregulated in tumors.
Recent studies show several underlying mechanisms
playing key roles in regulating miR-145 expression, espe-
cially in relation to p53, the central tumor suppressor.
Suh et al. found that downregulation of miR-145 was
mediated through DNA methylation and p53 mutation
pathways [40], which frequently occur in various malignanttumors. p53 can enhance post-transcriptional maturation
of miR-145 in response to DNA damage, and transcrip-
tionally inactive p53 mutants result in attenuation of
miRNA biological processing activity and predict worse
prognosis in patients with low miR-145 expression [41].
Loss of miR-145 expression is also observed frequently in
KRAS-mutated pancreatic cancer, and the downregulation
of miR-145 requires Ras-responsive element-binding pro-
tein (RREB1) to repress its promoter [42]. In addition,
Sachdeva et al. suggested that a regulatory system of
miR-145 involving the Akt and CCAAT/enhancer binding
protein beta (C/EBP-β) may contribute to the downregula-
tion of miR-145 in cancer cells [43] (Figure 1).
Based on the respective results of the analyzed studies,
we found that genetic background, pathology, or disease
type seemed to have specific effects on the association of
miR-145 expression and patient prognosis. In addition,
both of the overall analyses for patient survival and dis-
ease progression presented significant heterogeneity. All
of these data demonstrated that the pooled results of over-
all analyses are crude and cannot give accurate values of
miR-145 for prognosis. Stratified analyses based on ethnic
affiliation, pathology, or disease categories should be
carried out to minimize the impact of heterogeneity.
Our stratified analyses provide further confirmation
that high miR-145 expression can predict favorable OS
for patients both in White and Asian subgroups, but the
association in Whites (HR = 0.67) is not as strong as in
Asians (HR = 0.35). In addition, the high expression of
miR-145 can predict better PFS in Asians, but not in
Whites. These discrepancies might be due to different
hereditary backgrounds and environmental exposure be-
cause previous studies have reported diverse expression
levels and prognostic values of specific miRNAs in differ-
ent ethnic groups [44-46]. Pathological types also had a
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High expression of miR-145 seemed to be predict favor-
able OS in patients with SCC or glioblastoma but not
adenocarcinoma, but these results need to be confirmed
by further research.
These results indicate that miR-145 is a promising bio-
marker to predict prognosis for patients with cancers.
However, the conclusion is not sufficiently persuasive,
and needs to be further refined for several reasons. First,
no independent studies for black were included in our
analysis, and this omission might hinder comprehensive
investigation. Second, the number of analyzed studies
was not adequate, which weakens the reliability of our
results and hindered the execution of some subgroup
analyses. Furthermore, all the studies included in our
meta-analysis were retrospective, and no prospective
studies were available, which also weakens the values of
pooled results. Third, although there was no evidence of
obvious publication bias in this meta-analysis, there is a
possibility of language bias because only studies published
in English were included. In addition, the tendency for
authors and journals to publish only studies with positive
results may also be a source of bias. Fourth, the expression
of miR-145 was detected by tissue samples in all of the
analyzed articles except one, which used serum. Different
results might be obtained for detection of miR-145 in
peripheral blood samples. Furthermore, as a cancer bio-
marker, detection of miR-145 ub serum samples is more
convenient, faster and more acceptable for patients to
dynamically monitor their prognosis and therapeutic
effects through their lifetime. Therefore, the association
between patient prognosis and serum expression of
miR-145 should be further investigated. Fifth, it remains
unknown whether miR-145 should be used as an inde-
pendent biomarker or as part of a combination of sev-
eral biomarkers for predicting tumor prognosis. Using
Cox proportional regression analysis, Avgeris et al.
demonstrated that patients with PCa who had lower
miR-145 expression exhibited a significantly higher risk
for disease recurrence. Furthermore, this unfavorable
prognosis, associated with low miR-145 expression, was
independent of patient Gleason score, clinical stage,
PSA levels, and age [20]. Law et al. also reported that miR-
145 independently coordinated the regulation of many
components along the IGF pathway via its multigene tar-
gets, and was an independent prognostic predictor [9]. By
contrast, Huang et al. claimed that the downregulation of a
combination of six miRNAs including miR-145 was signifi-
cantly correlated with advanced stage, lymph node metas-
tasis, and poor prognosis in small cell carcinoma of the
cervix [26]. Liu et al. also reported that Fascin Homolog 1
(FSCN1) could be co-regulated by miR-43 and miR-145,
and suggested the combination of miR-143 and miR-145
as a potential biomarker for the prognosis of esophagealcancer [47]. The combined application of miR-145 with
other miRNAs might confer more specificity for pre-
dicting patient prognosis in various malignant diseases,
but this hypothesis needs to be proved by more clinical
research.
Conclusions
Our meta-analysis results indicate that high miR-145
expression is more suitable as a biomarker to predict
favorable patient survival rather than to predict tumor
progression, especially for SCC and glioblastoma in Asians.
Given the current insufficient evidence, further inves-
tigations and more studies are needed to focus on the
relationship between miR-145 expression and patient
prognosis.
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